You are here:

Forthcoming Submission: avelumab (Bavencio)

Indication: indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC)

Drug Details

Drug Name: avelumab (Bavencio)
Drug Manufacturer: Merck Serono Europe Limited / Pfizer Limited
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
5/02/2018
SMC Meeting Date: Q2 2018
Advice Due: Q2 2018

Back